Epic Pharma, LLC obtained FDA approval on May 28, 1999, for oral meperidine hydrochloride, likely securing a supply foothold in a niche segment of the short-acting opioid market that faces increasing withdrawal due to safety concerns. This authorization allows the manufacturer to compete for a diminishing share of demand driven by patients and clinicians seeking alternatives to drugs with neurotoxicity profiles.